Extracorporeal CO2 Removal Devices Market Size & Growth Analysis to 2030

The global extracorporeal CO2 removal devices market size was accounted at around USD 90 million in 2024 and anticipated to register a significant CAGR of over 7% during the forecast period from 2025 to 2030. The market is experiencing steady growth, driven by the increasing prevalence of respiratory conditions such as chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS). The market growth is attributed to technological advancements that have led to the development of more compact and portable devices, enhancing their accessibility and adoption in clinical settings. The COVID-19 pandemic also highlighted the importance of these devices, as they played a crucial role in managing severe respiratory complications associated with the virus.​

North America currently holds the largest market share, owing to its advanced healthcare infrastructure and high adoption rates of innovative medical technologies. However, the Asia-Pacific region is anticipated to witness the fastest growth during the forecast period, fueled by a large patient population, increasing awareness of respiratory diseases, and rising healthcare investments. Despite the positive outlook, challenges such as the high cost of devices and the need for specialized training for healthcare professionals may hinder market expansion in certain regions. Key players in the market include Medtronic, Getinge AB, Xenios AG, ALung Technologies, and ESTOR S.P.A., who are focusing on product innovation and strategic partnerships to strengthen their market position.

Market Snapshot:

Market Drivers:

The extracorporeal CO₂ removal (ECCO₂R) devices market is primarily driven by the escalating prevalence of respiratory conditions such as chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS). According to the World Health Organization, COPD was the fourth leading cause of death globally in 2021, resulting in approximately 3.5 million deaths. The increasing incidence of these conditions has led to a heightened demand for advanced respiratory support systems. ECCO₂R devices offer a less invasive alternative to mechanical ventilation, improving patient outcomes and reducing hospital stays. Furthermore, the aging global population, which is more susceptible to respiratory ailments, contributes to the growing need for such devices.​

Technological advancements have significantly influenced the ECCO₂R market. Innovations have led to the development of more efficient, compact, and user-friendly devices. For instance, the integration of artificial intelligence and machine learning has enhanced patient monitoring and treatment personalization. Additionally, the emergence of wearable and portable ECCO₂R devices has transformed critical care practices by offering prolonged respiratory support and enhanced patient mobility. These technological strides not only improve the efficacy of treatments but also expand the applicability of ECCO₂R devices across various healthcare settings.​

Market Trends:

Technological Advancements and Innovation: One of the most prominent trends in the ECCO₂R market is the rapid pace of technological innovation. Manufacturers are investing heavily in research and development to create more efficient, compact, and user-friendly devices. Advanced features, such as real-time monitoring, automated flow rate adjustments, and data integration systems, are being incorporated to support better decision-making for clinicians. Moreover, artificial intelligence (AI) and machine learning are being explored to predict patient responses, optimize CO₂ removal rates, and customize therapy in real time. These technological enhancements not only improve clinical outcomes but also reduce the workload on healthcare providers, making the devices more practical in high-demand critical care environments.

Shift Toward Minimally Invasive Respiratory Support: Another key trend is the healthcare industry’s growing preference for less invasive methods of supporting respiratory function, especially for patients suffering from severe lung diseases such as COPD and ARDS. ECCO₂R offers a promising alternative to traditional mechanical ventilation, which often involves high airway pressures and can lead to complications like barotrauma or ventilator-associated pneumonia (VAP). By enabling CO₂ removal without aggressive ventilation settings, ECCO₂R devices help reduce lung injury and allow the lungs to rest and heal. This trend is especially relevant in managing complex cases where standard ventilation strategies are either ineffective or risky.

Growth of Portable and Wearable ECCO₂R Devices: There is a rising interest in the development and adoption of portable and wearable ECCO₂R systems. These next-generation devices offer enhanced patient mobility, allowing certain therapies to continue outside of traditional ICU settings. For patients with chronic respiratory failure, these portable solutions represent a significant improvement in quality of life, as they can receive continuous respiratory support while maintaining some level of independence. This trend aligns with the broader movement in healthcare toward decentralized and home-based care, especially in aging populations and in regions where hospital access is limited.

Expanding Use in Critical and Post-Operative Care Settings: ECCO₂R devices are increasingly being used in various critical care scenarios, including as a bridge therapy for lung transplantation, during post-operative recovery from major surgeries, and in cases of drug overdose or metabolic acidosis that result in respiratory compromise. Hospitals and intensive care units are recognizing the value of ECCO₂R in reducing the duration of mechanical ventilation and shortening ICU stays, which ultimately lowers healthcare costs. As clinical studies continue to validate the safety and effectiveness of ECCO₂R in broader applications, its integration into standard treatment protocols is expected to rise.

Market Opportunities:

The global extracorporeal CO₂ removal (ECCO₂R) devices market is poised for significant growth, driven by several emerging opportunities. One notable opportunity lies in the expansion into emerging economies, particularly in the Asia-Pacific region. Countries like India and China are experiencing a rise in respiratory diseases due to factors such as urbanization and air pollution. This has led to an increased demand for advanced respiratory care solutions. The growing healthcare infrastructure and increasing awareness about respiratory care in these regions present lucrative opportunities for market players to expand their presence.

Another significant opportunity is the development of portable and user-friendly ECCO₂R devices. Advancements in membrane technology and device miniaturization are enabling the creation of more efficient and compact devices. These innovations are particularly beneficial for outpatient settings and home care, where patients require mobility and ease of use. The integration of advanced technologies such as artificial intelligence and telemedicine into ECCO₂R devices is also enhancing their capabilities, leading to better patient outcomes and streamlined operations. In 2024, Medtronic launched VitalFlow™, a new Extracorporeal Membrane Oxygenation (ECMO) system, which includes advanced features designed to improve patient care during critical respiratory failure situations. This reflects the growing focus on making these life-saving technologies more accessible, portable, and easier to use in a wide range of clinical environments.

Market Segment Insights:

By Product Type:

The global extracorporeal CO2 removal devices market is bifurcated into product type, access, application, end-use, and geography. On the basis of product type, the extracorporeal CO₂ machines sub-category dominates the market in 2024 due to its central role in providing the core therapy for patients with respiratory failure. These machines, which are typically integrated with advanced technologies such as real-time monitoring, automated CO₂ removal adjustments, and AI-powered predictive analytics, are critical in treating conditions like ARDS, COPD, and acute respiratory distress. The growing prevalence of such respiratory conditions, particularly in critical care and emergency settings, has driven the demand for more sophisticated and efficient machines. As healthcare systems continue to focus on improving patient outcomes and reducing complications associated with traditional mechanical ventilation, the importance of ECCO₂R machines has become more pronounced.

Moreover, the ability of Extracorporeal CO₂ Machines to offer precise and controlled CO₂ removal, along with their role in minimizing ventilator-associated complications, makes them a preferred choice in managing severe respiratory distress. With advancements in machine miniaturization, portability, and ease of use, the adoption of these devices is expanding across both hospital ICUs and outpatient settings. This segment also benefits from continuous innovations aimed at improving device efficiency, reducing operational costs, and enhancing patient comfort, further solidifying its dominance in the market. As the healthcare sector increasingly adopts these devices for both acute and long-term care, the demand for high-performance Extracorporeal CO₂ Machines is expected to remain strong, driving the segment’s continued market leadership.

By Application:

On the basis of application, the global ECCO₂R devices market is segmented into acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), bridge to lung transplant, and others. By application, the bridge to lung transplant sub-category dominated the market and holds the largest revenue share of over 1/3 of the global market in 2024. This application has become a vital component in managing patients with end-stage lung disease who are awaiting a lung transplant. The role of ECCO₂R devices in stabilizing patients during the waiting period for a transplant is critical, as they help maintain optimal blood gas levels, particularly CO₂, and prevent further deterioration of respiratory function. With the limited availability of donor organs and the high demand for lung transplants, ECCO₂R systems are increasingly being used to extend the survival and quality of life for these patients until a suitable donor lung becomes available. This segment continues to lead the market, driven by the rising demand for lung transplants and the life-saving role of ECCO₂R devices in this scenario.

On the other hand, the acute respiratory distress syndrome (ARDS) segment is growing at the fastest compound annual growth rate (CAGR) in the Extracorporeal CO₂ Removal Devices Market. The surge in ARDS cases, especially those linked to viral infections such as COVID-19, is a significant factor contributing to the rapid growth of this segment. ARDS is a leading cause of respiratory failure in critically ill patients, and ECCO₂R devices provide effective support by removing excess CO₂ and alleviating the strain on the lungs. As the healthcare industry increasingly adopts ECCO₂R devices to manage ARDS, and with the ongoing need for alternative solutions to traditional mechanical ventilation, this segment is expanding rapidly. The demand for ECCO₂R therapy in ARDS cases is expected to continue growing at an accelerated pace, making it the fastest-growing segment in the market.

The extracorporeal CO2 removal devices market research report presents the analysis of each segment from 2020 to 2030 considering 2024 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2025 to 2030.

Historical & Forecast Period

• 2020-23 – Historical Year
• 2024 – Base Year
• 2025-2030 – Forecast Period

Market Segmentation:

By Product Type:

• Extracorporeal CO2 Machines
• Disposables
• Others

By Access:

• Venovenous
• Arteriovenous

By Application:

• Acute Respiratory Distress Syndrome (ARDS)
• Chronic Obstructive Pulmonary Disease (COPD)
• Bridge to Lung Transplant
• Others

By End-Use:

• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis:

Geographically, the North America dominated the global extracorporeal CO₂ removal devices market in 2024, holding a significant share, primarily driven by the United States. The country’s advanced healthcare infrastructure, high rates of respiratory diseases like Chronic Obstructive Pulmonary Disease (COPD) and acute respiratory distress syndrome (ARDS), and its early adoption of cutting-edge medical technologies have positioned it at the forefront of the ECCO₂R market. The increasing prevalence of respiratory disorders due to factors such as aging populations, environmental pollution, and lifestyle-related diseases contributes to the growing demand for these devices. The widespread application of ECCO₂R technology in critical care units, especially in intensive care settings, further accelerates market growth. Additionally, the presence of major medical device manufacturers and the favorable regulatory environment in the United States have made North America a hub for medical innovation, making it the leading region for ECCO₂R adoption.

A recent initiative that strengthens North America’s dominance in respiratory care and, by extension, the ECCO₂R market, is the American Lung Association’s establishment of its Research Institute in 2023. The institute is pledging to increase its investment in lung disease research to USD 25 million annually. This commitment is aimed at advancing scientific understanding and treatment of lung diseases, which include conditions such as COPD, ARDS, and pulmonary fibrosis—all of which contribute to the growing demand for technologies like ECCO₂R. This significant investment highlights the continued prioritization of respiratory health in the United States and underscores the region’s ongoing commitment to improving treatment options. With increased research funding and the development of advanced therapies, including ECCO₂R devices, the region is poised to continue leading the market for respiratory medical technologies. The American Lung Association’s pledge will not only foster innovation but also improve patient outcomes, supporting the expanding adoption of ECCO₂R devices in North America.

Competitive Landscape:

Some of the prominent market players operating in the global extracorporeal CO2 removal devices market are Medtronic, Getinge AB, Xenios AG, ALung Technologies, Inc., and ESTOR S.P.A. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.

Recent Developments:

• In October 2023, Praxis received FDA clearance for its EndoCore EBUS-TBNA biopsy device, which is designed to enhance the accuracy and efficiency of lung biopsies. This innovative device aims to improve patient outcomes by enabling better tissue sampling during endobronchial ultrasound procedures, offering a more precise and effective way to diagnose lung conditions.
• In October 2022, ALung Technologies began evaluating the Hemolung RAS to assess its safety and efficacy in providing low-flow extracorporeal carbon dioxide removal (ECCO₂R). The goal was to explore its potential as an alternative or adjunct to invasive mechanical ventilation for patients requiring respiratory support due to an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).

Key Companies:

• Medtronic
• Getinge AB
• Xenios AG
• ALung Technologies, Inc.
• ESTOR S.P.A.
• Medica S.p.A.
• Aferetica S.r.l.
• Fresenius Medical Care
• LivaNova PLC
• Maquet Holding GmbH

Key Questions Answered by Extracorporeal CO2 Removal Devices Market Report

• Global extracorporeal CO2 removal devices market forecasts from 2025-2030
• Regional market forecasts from 2025-2030 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
• Country-level forecasts from 2025-2030 covering 15 major countries from the regions as mentioned above
• Extracorporeal CO2 removal devices submarket forecasts from 2025-2030 covering the market by product type, access, application, end-use, and geography
• Various industry models such as SWOT analysis, Value Chain Analysis about the market
• Analysis of the key factors driving and restraining the growth of the global, regional, and country-level extracorporeal CO2 removal devices markets from 2025-2030
• Competitive Landscape and market positioning of top 10 players operating in the market